KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Biogen (BIIB) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $779.9 million.

  • Biogen's Accumulated Depreciation & Amortization rose 1584.97% to $779.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $779.9 million, marking a year-over-year increase of 1584.97%. This contributed to the annual value of $779.9 million for FY2025, which is 1584.97% up from last year.
  • Biogen's Accumulated Depreciation & Amortization amounted to $779.9 million in Q4 2025, which was up 1584.97% from $579.7 million recorded in Q3 2025.
  • Biogen's Accumulated Depreciation & Amortization's 5-year high stood at $779.9 million during Q4 2025, with a 5-year trough of $102.6 million in Q1 2021.
  • Its 5-year average for Accumulated Depreciation & Amortization is $361.5 million, with a median of $353.8 million in 2021.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 3947.37% in 2022, then plummeted by 2152.34% in 2023.
  • Biogen's Accumulated Depreciation & Amortization (Quarter) stood at $487.7 million in 2021, then increased by 6.29% to $518.4 million in 2022, then decreased by 4.55% to $494.8 million in 2023, then skyrocketed by 36.05% to $673.2 million in 2024, then grew by 15.85% to $779.9 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $779.9 million for Q4 2025, versus $579.7 million for Q3 2025 and $377.5 million for Q2 2025.